CARA Cara Therapeutics, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

CARA [NASD]

Cara Therapeutics, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-2.55	Insider Own	2.60%	Shs Outstand	46.73M	Perf Week	0.23%
Market Cap	821.22M	Forward P/E	-	EPS next Y	-2.46	Insider Trans	-4.96%	Shs Float	42.47M	Perf Month	16.54%
Income	-113.30M	PEG	-	EPS next Q	-0.67	Inst Own	70.40%	Short Float	9.45%	Perf Quarter	20.30%
Sales	23.60M	P/S	34.80	EPS this Y	-20.90%	Inst Trans	0.01%	Short Ratio	7.27	Perf Half Y	10.59%
Book/sh	3.43	P/B	5.11	EPS next Y	5.70%	ROA	-53.80%	Target Price	-	Perf Year	-31.00%
Cash/sh	2.57	P/C	6.83	EPS next 5Y	-	ROE	-68.80%	52W Range	8.88 - 27.55	Perf YTD	8.88%
Dividend	-	P/FCF	-	EPS past 5Y	-24.10%	ROI	-59.40%	52W High	-36.33%	Beta	1.86
Dividend %	-	Quick Ratio	4.10	Sales past 5Y	44.30%	Gross Margin	-	52W Low	97.52%	ATR	0.81
Employees	67	Current Ratio	4.10	Sales Q/Q	84.10%	Oper. Margin	-	RSI (14)	60.65	Volatility	4.52% 4.86%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-11.50%	Profit Margin	-	Rel Volume	0.55	Prev Close	17.53
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 11 AMC	Payout	-	Avg Volume	551.69K	Price	17.54
Recom	1.70	SMA20	3.07%	SMA50	9.14%	SMA200	4.82%	Volume	303,276	Change	0.06%

Apr-21-20

Reiterated

H.C. Wainwright

Buy

$30 → $33

Aug-12-19

Reiterated

H.C. Wainwright

Buy

$31 → $30

May-29-19

Reiterated

Laidlaw

Buy

$26 → $32

Feb-06-19

Resumed

Jefferies

Buy

$22

Jan-15-19

Initiated

BofA/Merrill

Neutral

$19

Sep-21-18

Initiated

Cantor Fitzgerald

Overweight

Sep-13-18

Initiated

Jefferies

Buy

$30

Aug-08-18

Reiterated

Stifel

Buy

$22 → $26

Jun-28-18

Reiterated

H.C. Wainwright

Buy

$24 → $26

Mar-12-18

Resumed

H.C. Wainwright

Buy

$22

Feb-12-18

Upgrade

Janney

Neutral → Buy

Jan-19-18

Initiated

Seaport Global Securities

Buy

$27

Jun-30-17

Reiterated

Stifel

Buy

$24 → $20

Jun-30-17

Reiterated

Laidlaw

Buy

$35 → $30

Jun-30-17

Downgrade

Janney

Buy → Neutral

Mar-28-17

Reiterated

Laidlaw

Buy

$20 → $35

Mar-28-17

Reiterated

H.C. Wainwright

Buy

$22 → $30

Mar-10-17

Reiterated

Laidlaw

Buy

$17 → $20

Oct-13-16

Initiated

H.C. Wainwright

Buy

$20

Aug-08-16

Reiterated

Needham

Buy

$27 → $23

Jul-13-20 02:47PM	Cara Therapeutics'(NASDAQ:CARA) Share Price Is Down 31% Over The Past Year. Simply Wall St.
Jul-08-20 01:34PM	Is Cara Therapeutics Inc (CARA) A Good Stock To Buy? Insider Monkey
Jun-30-20 02:07PM	Top Marijuana Stocks on the NASDAQ for July 2020 Investopedia
07:00AM	Cara Therapeutics Expands Board of Directors with Appointment of Susan Shiff, Ph.D., M.B.A. GlobeNewswire
Jun-25-20 06:04PM	Edited Transcript of CARA.OQ earnings conference call or presentation 11-May-20 8:30pm GMT Thomson Reuters StreetEvents
Jun-17-20 07:00AM	Cara Therapeutics Announces Completion of Interim Statistical Assessment for KARE Phase 2 Trial of Oral KORSUVA in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus GlobeNewswire
May-27-20 04:01PM	Cara Therapeutics to Present at the Jefferies Virtual Healthcare Conference GlobeNewswire
May-15-20 11:00AM	Is Cara Therapeutics (CARA) Stock a Solid Choice Right Now? Zacks
May-12-20 06:00AM	Cara Therapeutics Inc (CARA) Q1 2020 Earnings Call Transcript Motley Fool
May-11-20 05:55PM	Cara Therapeutics (CARA) Reports Q1 Loss, Tops Revenue Estimates Zacks +11.36%
04:01PM	Cara Therapeutics Reports First Quarter 2020 Financial Results GlobeNewswire
May-07-20 07:00AM	Cara Therapeutics to Present at the Virtual BofA Securities 2020 Health Care Conference GlobeNewswire
May-04-20 04:01PM	Cara Therapeutics to Announce First Quarter 2020 Financial Results on May 11, 2020 GlobeNewswire
Apr-29-20 07:14AM	Better Buy: Cara Therapeutics vs. Sangamo Therapeutics Motley Fool
07:03AM	Will Cara Therapeutics (NASDAQ:CARA) Spend Its Cash Wisely? Simply Wall St.
Apr-28-20 12:34PM	Earnings Preview: Cara Therapeutics (CARA) Q1 Earnings Expected to Decline Zacks
Apr-21-20 08:07AM	Cara Therapeutics' Shares March Higher, Can It Continue? Zacks
01:30AM	Cara Therapeutics and Vifor Fresenius Medical Care Renal Pharma Announce Positive Results From Global KALM-2 Pivotal Phase 3 Trial of KORSUVATM Injection in Hemodialysis Patients with Pruritus GlobeNewswire
01:30AM	VFMCRP and Cara Therapeutics announce positive results from global KALM-2 pivotal phase-III trial of KORSUVA injection in haemodialysis patients with Pruritus Business Wire
Apr-20-20 09:40AM	Top Marijuana Stocks for April 2020 Investopedia
Apr-08-20 07:00AM	Cara Therapeutics to Present at the Virtual 19th Annual Needham Healthcare Conference GlobeNewswire +5.46%
Mar-25-20 07:00AM	Cara Therapeutics Reports Clinical Updates GlobeNewswire
Mar-23-20 06:49AM	Edited Transcript of CARA earnings conference call or presentation 27-Feb-20 9:30pm GMT Thomson Reuters StreetEvents +5.13%
Mar-10-20 01:45PM	3 Beaten-Down Biotech Stocks With Catalysts Just Around the Corner TipRanks
Feb-29-20 08:05AM	Cara Therapeutics, Inc. Just Reported And Analysts Have Been Cutting Their Estimates Simply Wall St.
Feb-27-20 05:55PM	Cara Therapeutics (CARA) Reports Q4 Loss, Misses Revenue Estimates Zacks
04:01PM	Cara Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results GlobeNewswire
Feb-20-20 04:01PM	Cara Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on February 27, 2020 GlobeNewswire
Feb-03-20 06:12AM	Does Cara Therapeutics, Inc.'s (NASDAQ:CARA) CEO Salary Reflect Performance? Simply Wall St.
Jan-15-20 05:26PM	New Cannabis Products Which Could Disrupt the Industry in 2020 Investopedia
Jan-08-20 04:01PM	Cara Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-19-19 09:32PM	Was Smart Money Right About Piling Into Cara Therapeutics Inc (CARA) in September? Insider Monkey
Dec-06-19 04:01PM	Cara Therapeutics Announces Equity Grants to Employees Under Inducement Plan GlobeNewswire
07:20AM	Edited Transcript of CARA earnings conference call or presentation 5-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Dec-04-19 10:02AM	Biotech Stock Roundup: Pipeline Updates From BIIB, AXSM, CARA, Collaborations & More Zacks
07:14AM	Investors Who Bought Cara Therapeutics (NASDAQ:CARA) Shares Three Years Ago Are Now Up 78% Simply Wall St.
Dec-03-19 04:01PM	Cara Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference GlobeNewswire -34.56%
08:41AM	Benzinga Pro's Top 6 Stocks To Watch For Tues., Dec. 3, 2019: CARA, VRAY, LE, KOD, FXI, ROKU Benzinga
07:35AM	UPDATE: Cara Therapeutics announces positive results in trial of treatment for chronic kidney disease MarketWatch
07:00AM	Cara Therapeutics Announces Positive Topline Data From Phase 2 Trial of Oral KORSUVA in Chronic Kidney Disease Patients with Moderate-to-Severe Pruritus GlobeNewswire
Nov-13-19 09:12AM	Is the Options Market Predicting a Spike in Cara Therapeutics (CARA) Stock? Zacks
Nov-12-19 04:01PM	Cara Therapeutics to Present at November Investor Conferences GlobeNewswire
Nov-11-19 07:00AM	Cara Therapeutics Announces Publication of Difelikefalin (KORSUVA Injection) KALM-1 Phase 3 Trial Results in the New England Journal of Medicine GlobeNewswire
Nov-05-19 06:35PM	Cara Therapeutics (CARA) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:01PM	Cara Therapeutics Reports Third Quarter 2019 Financial Results GlobeNewswire
Nov-01-19 07:00AM	Cara Therapeutics Announces Presentations at Kidney Week 2019 GlobeNewswire
Oct-29-19 04:40PM	Heres What Hedge Funds Think About Cara Therapeutics Inc (CARA) Insider Monkey
04:01PM	Cara Therapeutics to Announce Third Quarter 2019 Financial Results on November 5, 2019 GlobeNewswire
10:32AM	Analysts Estimate Cara Therapeutics (CARA) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-20-19 08:45AM	Have Insiders Been Selling Cara Therapeutics, Inc. (NASDAQ:CARA) Shares? Simply Wall St.
Oct-14-19 07:00AM	Cara Therapeutics Announces Completion of Interim Statistical Assessment and Small Increase in Target Enrollment for KALM-2 Phase 3 Global Trial of KORSUVA Injection in Hemodialysis Patients with Pruritus GlobeNewswire
Oct-01-19 02:23PM	First cannabis cafe in the U.S. opens in Los Angeles Yahoo Finance Video
Sep-26-19 04:01PM	Cara Therapeutics to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference GlobeNewswire -5.89%
Sep-19-19 10:11AM	How Much Of Cara Therapeutics, Inc. (NASDAQ:CARA) Do Institutions Own? Simply Wall St.
Aug-21-19 04:24PM	Cara Therapeutics Inc (CARA) Q2 2019 Earnings Call Transcript Motley Fool
11:44AM	10 Marijuana Stocks That Could See 100% Gains, If Not More InvestorPlace
07:04AM	Enteris BioPharma and Cara Therapeutics Enter into Licensing Agreement for Peptelligence® to Advance Development of Oral KORSUVA PR Newswire
07:00AM	Cara Therapeutics Enters into Commercial License Agreement with Enteris BioPharma, Inc. for Peptelligence® Oral Formulation Technology GlobeNewswire
Aug-19-19 12:34PM	Does Cara Therapeutics, Inc.'s (NASDAQ:CARA) CEO Pay Reflect Performance? Simply Wall St.
Aug-14-19 10:54AM	Edited Transcript of CARA earnings conference call or presentation 7-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-05-19 10:21AM	Here's Why Cara Therapeutics Rose 11.3% in July Motley Fool
07:21AM	Only These 9 Cannabis Stocks Rose in July Motley Fool
Jul-31-19 04:01PM	Cara Therapeutics to Announce Second Quarter 2019 Financial Results on August 7, 2019 GlobeNewswire
Jul-29-19 04:01PM	Cara Therapeutics Announces Closing of Its Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Jul-26-19 09:18PM	Weekly Cannabis Stock News: Auxly's Surprise Strategic Partner Investment Motley Fool
Jul-25-19 11:59AM	Cara Therapeutics Floats New Stock Issue Motley Fool -13.40%
Jul-24-19 08:42PM	Cara Therapeutics Announces Pricing of $126.5 Million Offering of Common Stock GlobeNewswire
04:01PM	Cara Therapeutics Announces Proposed Offering of Common Stock GlobeNewswire
Jul-22-19 07:00AM	Cara Therapeutics Announces No Modifications in Trial Size for Phase 2 Trial of Oral KORSUVA in Chronic Kidney Disease Patients with Pruritus after Completion of Interim Statistical Assessment GlobeNewswire
Jul-17-19 07:15PM	Cara Therapeutics Inc (CARA) CFO & Chief Strategy Officer Mani Mohindru Sold $935,775 of Shares GuruFocus.com
Jul-16-19 10:28AM	4 Strong Buy Biotechs With Big 3Q19 Catalysts TipRanks
Jul-14-19 07:30AM	3 Top Biotech Stocks to Buy for the 2nd Half of 2019 Motley Fool
Jul-13-19 07:56AM	Estimating The Fair Value Of Cara Therapeutics, Inc. (NASDAQ:CARA) Simply Wall St.
Jul-12-19 06:27PM	GuruFocus Value Idea Contest Sees 2 Winners! GuruFocus.com +6.91%
Jul-11-19 08:30AM	Enteris BioPharma's "Feasibility-to-Licensing" Partner, Cara Therapeutics, Initiates Phase 2 Trial of Peptelligence®-Engineered Oral KORSUVA for Pruritus in Patients with Atopic Dermatitis PR Newswire
Jul-09-19 07:00AM	Cara Therapeutics Announces Initiation of Phase 2 Trial of Oral KORSUVA (CR845/difelikefalin) for Pruritus in Patients with Atopic Dermatitis GlobeNewswire
Jul-02-19 07:16AM	Better Buy: GW Pharmaceuticals vs. Cara Therapeutics Motley Fool
Jun-26-19 07:00AM	Cara Therapeutics Announces Initiation of Phase 2 Trial of Oral KORSUVA (CR845/difelikefalin) for Pruritus in Patients with Primary Biliary Cholangitis (PBC) GlobeNewswire
Jun-13-19 07:04PM	Understanding Medical Cannabis vs. Recreational Cannabis Stocks Investopedia
Jun-02-19 09:09AM	Is Cara Therapeutics a Buy Now? Motley Fool
Jun-01-19 10:17AM	Cara Therapeutics surges 15.7% after company announces positive late-stage data for itchiness treatment MarketWatch
May-31-19 07:00AM	Cara Therapeutics to Present at the Jefferies 2019 Healthcare Conference GlobeNewswire
May-30-19 07:48AM	Cara Shares Up on Positive Phase III Data for Itchiness Drug Zacks
May-29-19 02:30PM	Cara Therapeutics Surges on Phase 3 Results for Itchiness Treatment TheStreet.com +19.97%
01:13PM	Stocks making the biggest moves midday: Canada Goose, Capri Holdings, General Mills & more CNBC
11:48AM	Cara Therapeutics Rallies On Positive Clinical Readout For Pruritis Drug Benzinga
11:36AM	Why Cara Therapeutics Stock Is Soaring Today Motley Fool
09:36AM	Announcing: Cara Therapeutics (NASDAQ:CARA) Stock Increased An Energizing 193% In The Last Three Years Simply Wall St.
09:02AM	Cara Therapeutics stock up 12.6% after company announces positive Phase 3 data for itchiness treatment MarketWatch
07:00AM	Cara Therapeutics Announces Positive Results From KALM-1 Pivotal Phase 3 Trial of KORSUVA Injection in Hemodialysis Patients with Pruritus GlobeNewswire
06:00AM	3 Top Small-Cap Stocks to Buy Right Now Motley Fool
May-28-19 10:43AM	3 Strong Buy Cannabis Biotech Stocks To Know Now TipRanks
May-23-19 08:09AM	Edited Transcript of CARA earnings conference call or presentation 7-May-19 8:30pm GMT Thomson Reuters StreetEvents
07:10AM	Even with a Pharma Arm, Canopy Growth Stock Is About Recreational Use InvestorPlace
May-17-19 06:00AM	3 Small-Cap Biotech Stocks You Can Buy Right Now Motley Fool
May-09-19 01:12PM	Did Hedge Funds Drop The Ball On Casa Therapeutics Inc (CARA) ? Insider Monkey
May-08-19 04:01PM	Cara Therapeutics to Present at the Bank of America Merrill Lynch 2019 Health Care Conference GlobeNewswire
02:23PM	Cara Therapeutics Inc (CARA) Q1 2019 Earnings Call Transcript Motley Fool
May-07-19 06:25PM	Cara Therapeutics (CARA) Reports Q1 Loss, Lags Revenue Estimates Zacks -5.71%
05:15PM	Cara: 1Q Earnings Snapshot Associated Press

Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) undergoing hemodialysis. The company is also developing Oral KORSUVA (CR845/difelikefalin), which has completed Phase II clinical trial for the treatment of pruritus in stage III-V CKD patients; in Phase II clinical trial for treating pruritus chronic liver disease; and in Phase II clinical trial for the treatment of pruritus associated with atopic dermatitis. In addition, it is developing CR845/difelikefalin Injection, which has completed Phase II/III clinical trial for the treatment of acute post-operative pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
CHALMERS DEREK T	President & CEO	Jul 01	Sale	17.11	5,000	85,550	961,421	Jul 02 04:40 PM
Goncalves Joana	Chief Medical Officer	Jun 12	Sale	15.20	10,627	161,530	35,373	Jun 12 06:00 PM
CHALMERS DEREK T	President & CEO	Jun 03	Sale	16.01	4,300	68,843	966,421	Jun 03 07:53 PM
Ives Jeffrey L.	Director	Jun 01	Option Exercise	9.94	1,000	9,940	7,000	Jun 03 07:51 PM
CHALMERS DEREK T	President & CEO	Jun 01	Sale	16.00	700	11,200	970,721	Jun 03 07:53 PM
Ives Jeffrey L.	Director	Jun 01	Sale	16.00	1,000	16,000	6,000	Jun 03 07:51 PM
CHALMERS DEREK T	President & CEO	May 22	Sale	16.00	371	5,936	971,421	May 22 06:26 PM
CHALMERS DEREK T	President & CEO	May 21	Sale	16.00	3,500	56,000	971,792	May 22 06:26 PM
CHALMERS DEREK T	President & CEO	May 20	Sale	16.00	1,200	19,200	975,292	May 22 06:26 PM
Ives Jeffrey L.	Director	May 12	Option Exercise	9.94	2,500	24,850	8,500	May 14 08:02 PM
CHALMERS DEREK T	President & CEO	May 12	Sale	16.00	4,929	78,864	976,492	May 14 08:04 PM
Ives Jeffrey L.	Director	May 12	Sale	16.00	2,500	40,000	6,000	May 14 08:02 PM
Ives Jeffrey L.	Director	Apr 21	Option Exercise	9.94	2,500	24,850	8,500	Apr 21 07:09 PM
Terrillion Scott	Sec'y; Chief Compliance & G.C.	Apr 21	Sale	15.56	2,721	42,339	38,382	Apr 21 06:50 PM
Menzaghi Frederique Ph.D.	Chief Scientific Off,SVP-R&D	Apr 21	Sale	15.58	12,894	200,889	104,492	Apr 21 06:49 PM
CHALMERS DEREK T	President & CEO	Apr 21	Sale	15.56	6,348	98,775	981,421	Apr 21 06:47 PM
Ives Jeffrey L.	Director	Apr 21	Sale	16.00	2,500	40,000	6,000	Apr 21 07:09 PM
Ives Jeffrey L.	Director	Mar 04	Option Exercise	9.94	2,500	24,850	8,500	Mar 06 04:39 PM
Ives Jeffrey L.	Director	Mar 04	Sale	16.00	2,500	40,000	6,000	Mar 06 04:39 PM
Ives Jeffrey L.	Director	Feb 03	Option Exercise	9.94	2,500	24,850	8,500	Feb 05 05:01 PM
Ives Jeffrey L.	Director	Feb 03	Sale	16.23	2,500	40,575	6,000	Feb 05 05:01 PM
Ives Jeffrey L.	Director	Jan 02	Option Exercise	9.94	2,500	24,850	8,500	Jan 06 06:06 PM
CHALMERS DEREK T	President & CEO	Jan 02	Sale	16.05	10,000	160,500	917,769	Jan 06 06:05 PM
Ives Jeffrey L.	Director	Jan 02	Sale	16.13	2,500	40,325	6,000	Jan 06 06:06 PM
Terrillion Scott	Sec'y; Chief Compliance & G.C.	Dec 04	Sale	17.05	3,980	67,859	16,769	Dec 04 07:52 PM
Mohindru Mani	CFO & Chief Strategy Officer	Dec 04	Sale	17.05	4,755	81,073	17,441	Dec 04 07:50 PM
CHALMERS DEREK T	President & CEO	Dec 04	Sale	17.05	10,699	182,418	927,769	Dec 04 07:47 PM
Ives Jeffrey L.	Director	Dec 02	Option Exercise	5.32	2,500	13,300	8,500	Dec 04 07:49 PM
Ives Jeffrey L.	Director	Dec 02	Sale	25.83	2,500	64,575	6,000	Dec 04 07:49 PM
CHALMERS DEREK T	President & CEO	Dec 02	Sale	25.79	10,000	257,900	918,468	Dec 04 07:47 PM
Ives Jeffrey L.	Director	Nov 01	Option Exercise	5.32	2,500	13,300	8,500	Nov 05 06:21 PM
CHALMERS DEREK T	President & CEO	Nov 01	Sale	20.79	5,000	103,950	928,468	Nov 05 06:07 PM
Ives Jeffrey L.	Director	Nov 01	Sale	20.68	2,500	51,700	6,000	Nov 05 06:21 PM
Menzaghi Frederique Ph.D.	Chief Scientific Off,SVP-R&D	Oct 25	Sale	19.91	4,000	79,640	63,886	Oct 29 08:36 PM
Menzaghi Frederique Ph.D.	Chief Scientific Off,SVP-R&D	Oct 18	Sale	19.33	4,000	77,320	67,886	Oct 22 05:01 PM
Menzaghi Frederique Ph.D.	Chief Scientific Off,SVP-R&D	Oct 11	Sale	18.70	4,000	74,800	71,886	Oct 16 06:26 PM
Menzaghi Frederique Ph.D.	Chief Scientific Off,SVP-R&D	Oct 04	Sale	19.19	4,000	76,760	75,886	Oct 08 04:44 PM
Ives Jeffrey L.	Director	Oct 01	Option Exercise	5.32	2,500	13,300	8,500	Oct 03 09:19 PM
Ives Jeffrey L.	Director	Oct 01	Sale	18.21	2,500	45,525	6,000	Oct 03 09:19 PM
CHALMERS DEREK T	President & CEO	Oct 01	Sale	18.28	10,000	182,800	933,468	Oct 03 09:17 PM
Ives Jeffrey L.	Director	Sep 03	Option Exercise	5.32	2,500	13,300	8,500	Sep 05 05:37 PM
Ives Jeffrey L.	Director	Sep 03	Sale	23.31	2,500	58,275	6,000	Sep 05 05:37 PM
Menzaghi Frederique Ph.D.	Chief Scientific Off,SVP-R&D	Sep 03	Sale	22.92	20,000	458,400	79,886	Sep 05 05:38 PM
CHALMERS DEREK T	President & CEO	Sep 03	Sale	23.26	5,000	116,300	943,468	Sep 05 05:36 PM
Ives Jeffrey L.	Director	Aug 01	Option Exercise	5.32	2,500	13,300	8,500	Aug 05 05:32 PM
Menzaghi Frederique Ph.D.	Chief Scientific Off,SVP-R&D	Aug 01	Sale	23.24	20,000	464,800	99,886	Aug 05 05:33 PM
CHALMERS DEREK T	President & CEO	Aug 01	Sale	23.27	10,000	232,700	948,468	Aug 05 05:31 PM
Ives Jeffrey L.	Director	Aug 01	Sale	23.24	2,500	58,100	6,000	Aug 05 05:32 PM
Menzaghi Frederique Ph.D.	Chief Scientific Off,SVP-R&D	Jul 17	Sale	27.50	8,996	247,390	119,886	Jul 19 05:47 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience